SPN-810 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Impulsive Aggression Comorbid With ADHD

Conditions

Impulsive Aggression Comorbid With ADHD

Trial Timeline

Jun 1, 2011 → Oct 1, 2012

NCT ID

NCT01364662

About SPN-810 + Placebo

SPN-810 + Placebo is a phase 2 stage product being developed by Supernus Pharmaceuticals for Impulsive Aggression Comorbid With ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT01364662. Target conditions include Impulsive Aggression Comorbid With ADHD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03638466	Phase 2	Terminated	May 30, 2019	Nov 7, 2019	Attention Deficit Hyperactivity Disorder (ADHD)
NCT03597503	Phase 3	Terminated	Jul 31, 2018	Jan 22, 2020	Attention Deficit Hyperactivity Disorder
NCT01364662	Phase 2	Completed	Jun 1, 2011	Oct 1, 2012	Impulsive Aggression Comorbid With ADHD

Competing Products

2 competing products in Impulsive Aggression Comorbid With ADHD

See all competitors

Product	Company	Stage	Hype Score
Molindone	Supernus Pharmaceuticals	Phase 2	47
SPN-810M	Supernus Pharmaceuticals	Phase 1	28

Other Products from Supernus Pharmaceuticals

ZULRESSO®Approved

APOKYNApproved

SPN-812Approved

100mg SPN-812 + PlaceboApproved